GENinCode UK Ltd. (GB:GENI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GENinCode has partnered with Genesupport SA to provide the ROCA Test for ovarian cancer surveillance across Switzerland, making it accessible to over 11,000 women at high risk. This collaboration aims to improve early detection and treatment outcomes, leveraging the ROCA Test’s proven accuracy and extensive clinical evaluation. The partnership is set to enhance preventive healthcare options for women with genetic predispositions to ovarian cancer.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
